Tyruko is indicated as a single disease-modifying therapy (DMT) for adults diagnosed with highly active RRMS. This is the same indication that was approved by the European Commission
Pancreatic cancer is known for its poor prognosis and high mortality rate. With a combined annual death toll of 139,000 in the US and European Union, it is
The approval allows Oricell to commence clinical development of OriCAR-017 in the US, with immediate effect. Utilising Oricell’s platforms, including OriAb antibodies, OriCAR construct, and unique CMC know-how,
The treatment is intended for usage in adults with priorly untreated la/mUC. This development marks a significant step towards potentially offering an alternative to the current standard platinum-containing
The facility is designed to bolster in-house production of drug substances for Investigational New Drug (IND)-enabling studies and trials. This development is pivotal for the company’s proprietary and
UGN-102 for intravesical solution is a new drug formulation of mitomycin. The drug utilises UroGen’s proprietary RTGel technology, which allows for sustained release and prolonged exposure to bladder
The OpCT-001 iPSC cell therapy candidate is intended for treating primary photoreceptor diseases. The latest move marks the first iPSC therapy candidate to be licensed from the strategic
This collaboration aims to improve the evaluation process for CAR T therapy for cancer patients. It focuses on five crucial factors to ensure timely and personalised care for
The approval from the Ministry of Health, Labor and Welfare (MHLW) marks a significant milestone in the treatment of the ultra-rare, fatal paediatric disease characterised by accelerated aging.
Financial terms of the deal were undisclosed. The move is set to enhance Kindeva’s drug-delivery capabilities by adding a new platform to its portfolio. Kindeva CEO Milton Boyer
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.